Patents by Inventor Sourav Roy CHOUDHURY
Sourav Roy CHOUDHURY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240139340Abstract: The disclosure relates, in some aspects, to compositions and methods for enhanced delivery of a transgene to the central nervous system (CNS) of a subject. In some embodiments, the transgene is delivered by recombinant AAV (rAAV). In some embodiments, the method of enhancing transgene delivery comprises administering a blood brain barrier (BBB)-crossing molecule (e.g., K16ApoE) and an rAAV comprising a transgene to a subject.Type: ApplicationFiled: October 20, 2023Publication date: May 2, 2024Applicant: University of MassachusettsInventors: Miguel Sena Esteves, Ana Rita Batista, Sourav Roy Choudhury
-
Publication number: 20230407255Abstract: Provided herein are methods for determining the innate immunogenicity of a gene therapy agent in an individual. In particular, the methods involve the use of isolated dendritic cells to detect innate immunogenicity to a gene therapy agent. Exemplary gene therapy agents include adeno-associated virus (AAV) vectors, adenovirus vectors, lentivirus vectors, Herpes simplex virus (HSV) vectors or a lipid nanoparticles.Type: ApplicationFiled: April 12, 2023Publication date: December 21, 2023Inventors: Sourav Roy CHOUDHURY, Mona MOTWANI
-
Publication number: 20230405014Abstract: Provided herein are methods for enhancing gene therapy in an individual by administering an IRAK degrader with the gene therapy to suppress innate immunity to the gene therapy. In some embodiments, the gene therapy uses an adeno-associated virus (AAV) vector, an adenovirus vector, a lentivirus vector, a Herpes simplex virus (HSV) vector or a lipid nanoparticle. Also provided herein are methods for selecting an individual for treatment with an IRAK degrader in combination with a gene therapy agent.Type: ApplicationFiled: April 12, 2023Publication date: December 21, 2023Inventors: Sourav Roy CHOUDHURY, Mona MOTWANI, Christian MUELLER, John REED
-
Publication number: 20230405151Abstract: Provided herein are methods for enhancing gene therapy in an individual by administering an IRAK modulator (e.g., an IRAK-4 degrader) with the gene therapy to suppress innate immunity to the gene therapy. In some embodiments, the gene therapy uses an adeno-associated virus (AAV) vector, an adenovirus vector, a lentivirus vector, a Herpes simplex virus (HSV) vector or a lipid nanoparticle. Also provided herein are methods for selecting an individual for treatment with an IRAK modulator in combination with a gene therapy agent.Type: ApplicationFiled: April 12, 2023Publication date: December 21, 2023Inventors: Sourav Roy CHOUDHURY, Mona MOTWANI, Christian MUELLER, John REED
-
Patent number: 11826433Abstract: The disclosure relates, in some aspects, to compositions and methods for enhanced delivery of a transgene to the central nervous system (CNS) of a subject. In some embodiments, the transgene is delivered by recombinant AAV (rAAV). In some embodiments, the method of enhancing transgene delivery comprises administering a blood brain barrier (BBB)-crossing molecule (e.g., K16ApoE) and an rAAV comprising a transgene to a subject.Type: GrantFiled: February 2, 2017Date of Patent: November 28, 2023Assignee: University of MassachusettsInventors: Miguel Sena Esteves, Ana Rita Batista, Sourav Roy Choudhury
-
Publication number: 20230067741Abstract: The disclosure relates, in some aspects, to adeno-associated virus capsid proteins isolated from an in vivo library and recombinant adeno-associated viruses (rAAVs) comprising the same. In some aspects, the disclosure relates to isolated nucleic acids encoding AAV capsid proteins isolated from an in vivo library. In some embodiments, rAAVs and compositions described by the disclosure are useful for delivery of one or more transgenes to the muscle-tissue of a subject.Type: ApplicationFiled: September 7, 2022Publication date: March 2, 2023Applicants: University of Massachusetts, The Johns Hopkins University, Kennedy Krieger Institute, Inc.Inventors: Miguel Sena Esteves, Sourav Roy Choudhury, Kathryn Rae Wagner, Jennifer Gifford Green, Ana Rita Batista
-
Patent number: 11472848Abstract: The disclosure relates, in some aspects, to adeno-associated vims capsid proteins isolated from an in vivo library and recombinant adeno-associated viruses (rAAVs) comprising the same. In some aspects, the disclosure relates to isolated nucleic acids encoding AAV capsid proteins isolated from an in vivo library. In some embodiments, rAAVs and compositions described by the disclosure are useful for delivery of one or more transgenes to the muscle-tissue of a subject.Type: GrantFiled: April 26, 2019Date of Patent: October 18, 2022Assignees: University of Massachusetts, The Johns Hopkins University, Kennedy Krieger Institute, Inc.Inventors: Miguel Sena Esteves, Sourav Roy Choudhury, Kathryn Rae Wagner, Jennifer Gifford Green, Ana Rita Batista
-
Publication number: 20210324044Abstract: The disclosure in some aspects relates to recombinant adeno-associated viruses having distinct tissue targeting capabilities. In some aspects, the disclosure relates to gene transfer methods using the recombinant adeno-associated viruses. In some aspects, the disclosure relates to isolated AAV capsid proteins and isolated nucleic acids encoding the same.Type: ApplicationFiled: April 22, 2021Publication date: October 21, 2021Applicant: University of MassachusettsInventors: Miguel Sena Esteves, Sourav Roy Choudhury
-
Publication number: 20210238233Abstract: The disclosure relates, in some aspects, to adeno-associated vims capsid proteins isolated from an in vivo library and recombinant adeno-associated viruses (rAAVs) comprising the same. In some aspects, the disclosure relates to isolated nucleic acids encoding AAV capsid proteins isolated from an in vivo library. In some embodiments, rAAVs and compositions described by the disclosure are useful for delivery of one or more transgenes to the muscle-tissue of a subject.Type: ApplicationFiled: April 26, 2019Publication date: August 5, 2021Applicants: University of Massachusetts, The Johns Hopkins University, Kennedy Krieger Institute, Inc.Inventors: Miguel Sena Esteves, Sourav Roy Choudhury, Kathryn Rae Wagner, Jennifer Gifford Green, Ana Rita Batista
-
Patent number: 11014976Abstract: The disclosure in some aspects relates to recombinant adeno-associated viruses having distinct tissue targeting capabilities. In some aspects, the disclosure relates to gene transfer methods using the recombinant adeno-associated viruses. In some aspects, the disclosure relates to isolated AAV capsid proteins and isolated nucleic acids encoding the same.Type: GrantFiled: June 25, 2019Date of Patent: May 25, 2021Assignee: University of MassachusettsInventors: Miguel Sena Esteves, Sourav Roy Choudhury
-
Publication number: 20200354714Abstract: Aspects of the disclosure relate to barcoded chimeric adeno-associated virus (AAV) capsid libraries, chimeric capsids and related recombinant AAVs (rAAVs) identified using the libraries. Specifically, the chimeric AAV capsid libraries comprise a plurality of nucleic adds encoding AAV capsid proteins, wherein each nucleic acid (i) encodes a unique AAV capsid protein having distinct polypeptide regions of greater than six amino acids in length that are derived from at least two different AAV serotypes, and (ii) comprises a unique barcode sequence. Further disclosed are methods of preparing an AAV library and identifying AAV capsids tropic for a target tissue.Type: ApplicationFiled: May 21, 2020Publication date: November 12, 2020Applicant: University of MassachusettsInventors: Miguel Sena Esteves, Sourav Roy Choudhury
-
Patent number: 10711270Abstract: Aspects of the disclosure relate to barcoded chimeric adeno-associated virus (AAV) capsid libraries, chimeric capsids and related recombinant AAVs (rAAVs) identified using the libraries. Specifically, the chimeric AAV capsid libraries comprise a plurality of nucleic adds encoding AAV capsid proteins, wherein each nucleic acid (i) encodes a unique AAV capsid protein having distinct polypeptide regions of greater than six amino acids in length that are derived from at least two different AAV serotypes, and (ii) comprises a unique barcode sequence. Further disclosed are methods of preparing an AAV library and identifying AAV capsids tropic for a target tissue.Type: GrantFiled: October 2, 2015Date of Patent: July 14, 2020Assignee: University of MassachusettsInventors: Miguel Sena Esteves, Sourav Roy Choudhury
-
Publication number: 20190389934Abstract: The disclosure in some aspects relates to recombinant adeno-associated viruses having distinct tissue targeting capabilities. In some aspects, the disclosure relates to gene transfer methods using the recombinant adeno-associated viruses. In some aspects, the disclosure relates to isolated AAV capsid proteins and isolated nucleic acids encoding the same.Type: ApplicationFiled: June 25, 2019Publication date: December 26, 2019Applicant: University of MassachusettsInventors: Miguel Sena Esteves, Sourav Roy Choudhury
-
Patent number: 10370432Abstract: The disclosure in some aspects relates to recombinant adeno-associated viruses having distinct tissue targeting capabilities. In some aspects, the disclosure relates to gene transfer methods using the recombinant adeno-associated viruses. In some aspects, the disclosure relates to isolated AAV capsid proteins and isolated nucleic acids encoding the same.Type: GrantFiled: October 2, 2015Date of Patent: August 6, 2019Assignee: University of MassachusettsInventors: Miguel Sena Esteves, Sourav Roy Choudhury
-
Publication number: 20190038773Abstract: The disclosure relates, in some aspects, to compositions and methods for enhanced delivery of a transgene to the central nervous system (CNS) of a subject. In some embodiments, the transgene is delivered by recombinant AAV (rAAV). In some embodiments, the method of enhancing transgene delivery comprises administering a blood brain barrier (BBB)-crossing molecule (e.g., K16ApoE) and an rAAV comprising a transgene to a subject.Type: ApplicationFiled: February 2, 2017Publication date: February 7, 2019Applicant: University of MassachusettsInventors: Miguel Sena Esteves, Ana Rita Batista, Sourav Roy Choudhury
-
Publication number: 20180265571Abstract: The disclosure in some aspects relates to recombinant adeno-associated viruses having distinct tissue targeting capabilities. In some aspects, the disclosure relates to gene transfer methods using the recombinant adeno-associated viruses. In some aspects, the disclosure relates to isolated AAV capsid proteins and isolated nucleic acids encoding the same.Type: ApplicationFiled: October 2, 2015Publication date: September 20, 2018Applicant: University of MassachusettsInventors: Miguel Sena ESTEVES, Sourav Roy CHOUDHURY
-
Publication number: 20180265863Abstract: Aspects of the disclosure relate to barcoded chimeric adeno-associated virus (AAV) capsid libraries, chimeric capsids and related recombinant AAVs (rAAVs) identified using the libraries. Spedfically, the chimeric AAV capsid libraries comprise a plurality of nucleic adds encoding AAV capsid proteins, wherein each nucleic acid (i) encodes a unique AAV capsid protein having distinct polypeptide regions of greater than six amino acids in length that are derived from at least two different AAV serotypes, and (ii) comprises a unique barcode sequence. Further disdosed are methods of preparing an AAV library and identifying AAV capsids tropic for a target tissue.Type: ApplicationFiled: October 2, 2015Publication date: September 20, 2018Applicant: University of MassachusettsInventors: Miguel Sena ESTEVES, Sourav Roy CHOUDHURY